FDA Demands Proof, Not Just Protein, for Duchenne Therapy
FDA scrutinizes microdystrophin as surrogate for Duchenne treatment, demanding proof of clinical benefit.
2 min read
The FDA is demanding proof, not just protein levels, to approve Duchenne treatments, emphasizing the need for evidence that microdystrophin expression predicts real clinical benefit. This stance is part of the agency’s rigorous standard for surrogate endpoints, as outlined in the Federal Food, Drug, and Cosmetic Act.
Regulatory Consistency and Commercial Interests
Recent discussions around REGENXBIO’s RGX-202 have framed the FDA’s position as regulatory inconsistency, suggesting the agency is applying different standards to different sponsors. However, the core issue is whether microdystrophin expression is a reliable indicator of clinical benefit. The FDA is not being inconsistent but is instead adhering to its statutory obligation to ensure that surrogates are reasonably likely to predict actual patient outcomes.
Challenges with Biomarkers and Evidence
While REGENXBIO reported that 93% of boys in its Affinity Duchenne trial reached at least 10% microdystrophin expression, the functional improvements remain unclear. The correlation between expression levels and functional outcomes is based on limited data, raising concerns about the reliability of using microdystrophin as a surrogate.
Pfizer’s CIFFREO Trial and Its Implications
Pfizer’s CIFFREO trial, a Phase 3, double-blind, placebo-controlled study, showed high microdystrophin expression but no significant functional improvement. This highlights the risk of relying solely on biomarkers without robust clinical evidence. The trial’s results underscore the need for the FDA to demand more rigorous proof before approving therapies based on surrogate endpoints.
Long-Term Consequences and Regulatory Principles
The FDA’s approach is grounded in the principle that surrogates must reliably predict clinical benefit. Given the irreversible nature of early treatment decisions, the agency is justified in its demand for solid evidence. The stakes are high, as an inadequately validated therapy could limit future treatment options for patients.
Conclusion and Regulatory Framework
The FDA’s framework remains unchanged, requiring extensive evidence before a surrogate can substitute for clinical outcomes. The agency’s stance is a necessary safeguard to ensure that patients receive therapies that are both effective and safe, reflecting its commitment to rigorous regulatory standards.
